Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26102426 | 1.00 | CYP19A1 (0.45) | CYP19A1CYP3A4HSP90AA1HDAC8P2RX7 | |
| SCHEMBL11970656 | 1.00 | CYP19A1 (0.45) | CYP19A1CYP3A4HSP90AA1HDAC8P2RX7 | |
| SCHEMBL26105611 | 0.81 | CYP19A1 (0.45) | CYP19A1CYP3A4HSP90AA1P2RX7KDM4E | |
| SCHEMBL16091462 | 0.78 | CYP19A1 (0.52) | CYP19A1CYP3A4HSP90AA1P2RX7KDM4E | |
| SCHEMBL11970541 | 0.77 | CYP19A1 (0.41) | CYP19A1CYP3A4HSP90AA1 | |
| SCHEMBL29439780 | 0.76 | SMN1; SMN2 (0.55) | CYP3A4KDM4E | |
| SCHEMBL15192459 | 0.76 | SMN1; SMN2 (0.55) | CYP3A4KDM4E | |
| SCHEMBL29472057 | 0.76 | SMN1; SMN2 (0.55) | CYP3A4KDM4E | |
| SCHEMBL15193140 | 0.76 | SMN1; SMN2 (0.55) | CYP3A4KDM4E | |
| SCHEMBL1613102 | 0.76 | SMN1; SMN2 (0.55) | CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423075-B1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-09 | — | — | US | disclosed |
| EP-4423075-A1 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-09-04 | — | — | EP | disclosed |
| CN-118139854-A | Modulators of CCR6 receptors | 爱杜西亚药品有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023073082-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR4 | CYP19A1 3211/4885CYP3A4 2304/4885HSP90AA1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.